These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 12742232)
1. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Iguchi T; Miyakawa Y; Yamamoto K; Kizaki M; Ikeda Y Cell Signal; 2003 Jul; 15(7):719-27. PubMed ID: 12742232 [TBL] [Abstract][Full Text] [Related]
2. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051 [TBL] [Abstract][Full Text] [Related]
3. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Nakajima H; Magae J; Tsuruga M; Sakaguchi K; Fujiwara I; Mizuta M; Sawai K; Yamagishi H; Mizuta N Cancer Lett; 2007 Aug; 253(1):89-96. PubMed ID: 17316980 [TBL] [Abstract][Full Text] [Related]
4. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank MA; Phipps RJ; Rogers MJ Bone; 2001 Oct; 29(4):336-43. PubMed ID: 11595616 [TBL] [Abstract][Full Text] [Related]
5. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Takahashi R; Shimazaki C; Inaba T; Okano A; Hatsuse M; Okamoto A; Hirai H; Ashihara E; Nakagawa M Leuk Res; 2001 Jan; 25(1):77-83. PubMed ID: 11137564 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Ishikawa C; Matsuda T; Okudaira T; Tomita M; Kawakami H; Tanaka Y; Masuda M; Ohshiro K; Ohta T; Mori N Br J Haematol; 2007 Feb; 136(3):424-32. PubMed ID: 17233845 [TBL] [Abstract][Full Text] [Related]
7. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Iguchi T; Miyakawa Y; Saito K; Nakabayashi C; Nakanishi M; Saya H; Ikeda Y; Kizaki M Int J Oncol; 2007 Aug; 31(2):285-91. PubMed ID: 17611684 [TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631 [TBL] [Abstract][Full Text] [Related]
11. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784 [TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473 [TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
14. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872 [TBL] [Abstract][Full Text] [Related]
15. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Nishida S; Kikuichi S; Haga H; Yoshioka S; Tsubaki M; Fujii K; Irimajiri K Biol Pharm Bull; 2003 Jan; 26(1):96-100. PubMed ID: 12520182 [TBL] [Abstract][Full Text] [Related]
16. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. van beek E; Löwik C; van der Pluijm G; Papapoulos S J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520 [TBL] [Abstract][Full Text] [Related]
17. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Nishida S; Fujii Y; Yoshioka S; Kikuichi S; Tsubaki M; Irimajiri K Life Sci; 2003 Oct; 73(21):2655-64. PubMed ID: 13679234 [TBL] [Abstract][Full Text] [Related]
18. Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. Agabiti SS; Li J; Wiemer AJ Cell Death Dis; 2017 Mar; 8(3):e2678. PubMed ID: 28300835 [TBL] [Abstract][Full Text] [Related]
19. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Tsubaki M; Kato C; Nishinobo M; Ogaki M; Satou T; Ito T; Kusunoki T; Fujiwara K; Yamazoe Y; Nishida S Cancer Sci; 2008 Jan; 99(1):152-8. PubMed ID: 17979996 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates--mechanisms of action in multiple myeloma. Shipman CM; Rogers MJ; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher PI Acta Oncol; 2000; 39(7):829-35. PubMed ID: 11145441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]